0001104659-22-092204.txt : 20220817
0001104659-22-092204.hdr.sgml : 20220817
20220817162739
ACCESSION NUMBER: 0001104659-22-092204
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220815
FILED AS OF DATE: 20220817
DATE AS OF CHANGE: 20220817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Khattar Jack A.
CENTRAL INDEX KEY: 0001539937
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 221174421
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060317
4
1
tm2223647-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-08-15
0
0001356576
SUPERNUS PHARMACEUTICALS, INC.
SUPN
0001539937
Khattar Jack A.
C/O SUPERNUS PHARMACEUTICALS, INC.
9715 KEY WEST AVENUE
ROCKVILLE
MD
20850
1
1
0
0
President, CEO
Common Stock
2022-08-15
4
M
0
46575
0
A
788016
D
Common Stock
2022-08-15
4
M
0
10813
34.028
D
777203
D
Common Stock
2022-08-15
4
S
0
17302
34.028
D
759901
D
Common Stock
1047700
I
By the KBT Trust
Common Stock
4000
I
By son
Stock Appreciation Right
7.90
2022-08-15
4
M
0
46575
0
D
2023-02-05
Common Stock
46575
45425
D
Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.
Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.13, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
The stock appreciation right vested in four equal annual installments beginning on February 5, 2014.
/s/ Timothy C. Dec, as attorney-in-fact
2022-08-17